# Excelsior Sciences

> Excelsior Sciences is a New York City biotech building 'machine-native chemistry' - a way to make small molecules that machines can execute and AI can learn from. Its proprietary smart bloccs platform turns drug synthesis into a modular, automation-friendly, iterative process, closing the loop between AI-driven discovery and real-world manufacturing. Founded in 2024 and spun out of Deerfield Management, the company raised $95M in late 2025 to scale the platform and reshore U.S. drug discovery and production.

- **Founded:** 2024
- **Headquarters:** New York, New York, United States
- **Founders:** Michael Foley (Co-Founder & CEO), Jana Jensen (Co-Founder & COO), Martin (Marty) Burke (Co-Founder & Board Member), Bartosz Grzybowski (Co-Founder & Advisor)
- **Team size:** ~26 employees (reported ~18-26: scientists, software engineers, and automation specialists)
- **Products:** Smart Bloccs Platform, Closed-Loop Discovery & Manufacturing, Internal Therapeutics Pipeline
- **Notable:** Raised $95M total in late 2025 ($70M Series A + $25M New York State grant)., Assembled a marquee investor syndicate: Deerfield, Khosla Ventures, Sofinnova Partners, Eli Lilly, MIT, and others., Built a fully integrated synthesis-to-testing lab in Manhattan's Cure building.

## Products & services

- **Smart Bloccs Platform** — Modular, automation-friendly, function-infused and AI-readable chemical building blocks that assemble small molecules through iterative carbon-carbon bond formation - like tokens in a chemical language assembled the way peptides are. Integrates automated synthesis, high-throughput testing, and AI optimization in a single closed loop.
- **Closed-Loop Discovery & Manufacturing** — A unified workflow connecting AI-guided design, automated synthesis, biological testing, and continuous-flow scale-up under one roof, so a molecule can move from idea to production without re-inventing the chemistry.
- **Internal Therapeutics Pipeline** — Proprietary small-molecule drug programs developed on the smart bloccs platform, alongside partnered programs across therapeutics and materials science.

## Achievements

- Raised $95M total in late 2025 ($70M Series A + $25M New York State grant).
- Assembled a marquee investor syndicate: Deerfield, Khosla Ventures, Sofinnova Partners, Eli Lilly, MIT, and others.
- Built a fully integrated synthesis-to-testing lab in Manhattan's Cure building.
- Founding science backed by patented building-block chemistry from Marty Burke's University of Illinois lab.
- Research lineage published in Nature and Science (closed-loop / autonomous chemistry).

## Latest updates

- **2025-12** — Announced $95M in financing ($70M Series A + $25M Empire State Development grant) to scale the smart bloccs platform, fund its internal pipeline, and build partnerships across therapeutics and materials science.

## Links

- Website: https://excelsiorsci.com
- LinkedIn: https://www.linkedin.com/company/excelsior-sciences

---

Profile page: https://yespress.io/excelsior-sciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-07